The influence of VIP and epoprostenol on platelet CD62P expression and primary haemostasis in vitro

Platelets

Volumn 15, Issue 1, 2004, Pages 55-60

  Zwerina, Jochen ^a   Landsteiner, Harald ^a   Leitgeb, Ursula ^b   Volf, Ivo ^b   Petkov, Ventzislav ^b   Zimpfer, Michael ^a,b   Blaicher, Alex ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; PADGEM PROTEIN; PROSTACYCLIN; SODIUM CHLORIDE; THROMBOCYTE ACTIVATING FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; BLEEDING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ANALYSIS OF VARIANCE; ARACHIDONIC ACID; BLOOD PLATELETS; EPOPROSTENOL; FLOW CYTOMETRY; HEMOSTASIS; HUMANS; P-SELECTIN; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA;

EID: 1442290160     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953710032000159294     Document Type: Article

References (23)

1. Rashid A, Lehrman S, Romano P, Frishman W, Dobkin J, Reichel J. Primary pulmonary hypertension. Heart Dis 2000; 2(6): 422-30.
2. Lehrman S, Romano P, Frishman W, Rashid A, Dobkin J, Reichel J. Primary pulmonary hypertension and cor pulmonale. Cardiol Rev 2002; 10(5): 265-78.
3. Bjornsson J, Edwards W D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60(1): 16-25.
4. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22(3): 451-58.
5. Welsh C H, Hassell K L, Badesch D B, Kressin D C, Marlar R A. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110(3): 710-17.
6. Semenov A V, Kogan-Ponomarev M I, Ruda M I, Komarov A L, Panchenko E P, Chazova I E, et al. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension]. Ter Arkh 2000; 72(4): 15-20.
7. Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76-81.
8. Hoeper M M, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342(25): 1866-70.
9. Wax D, Garofano R, Barst R J. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116(4): 914-20.
10. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102(22): 2720-25.
11. Soderman C., Eriksson L S, Juhlin D A, et al. Effect of Vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin Physiol 1993; 13: 677-85.
12. Saga T, Said S I. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery and lung parenchyma. Trans Assoc Am Physicians 1984; 97: 304-10.
13. Maruno K, Absood A, Said S I. VIP inhibits basal and histamine- stimulated proliferation of human airway smooth muscle cells. Am J Physiol 1995; 268(6 Pt 1): L1047-L1051.
14. Park S K, Olson T A, Ercal N, Summers M, O'Dorisio M S. Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets. Blood 1996; 87(11): 4629-35.
15. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Organ distribution and characterization of porcine peptides (VIP, CGRP and PHI) that increase cAMP in rat platelets. Biochem Biophys Res Commun 1992; 187(3): 1587-93.
16. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111(9): 1339-46.
17. Gunaydin S, Imai Y, Takanashi Y, Seo K, Hagino I, Chang D, et al. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine. Cardiovasc Surg 2002; 10(2): 138-45.
18. Iwanaga T, Kitamura S, Hirose T, Said S I. Vasoactive intestinal peptide (VIP) protects against acid-induced acute lung injury in isolated perfused rat lungs. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27(7): 789-95.
19. Michelson A D. Flow cytometry: a clinical test of platelet function. Blood 1996; 87(12): 4925-36.
20. Favaloro E J. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7(2): 170-79.
21. D Alonzo G E, Barst R J, Ayres S M, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-49.
22. Friedman R, Mears J G, Barst R J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96(9): 2782-4.
23. Cox C P, Linden J, Said S I. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 1984; 5(2): 325-28.